Shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) have been given an average rating of “Moderate Buy” by the four research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $382.00.
A number of research analysts have commented on the company. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. Finally, Robert W. Baird upped their target price on shares of Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research note on Wednesday, February 14th.
View Our Latest Stock Analysis on Medpace
Insiders Place Their Bets
Hedge Funds Weigh In On Medpace
A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP lifted its holdings in shares of Medpace by 312.6% in the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after purchasing an additional 319,210 shares during the last quarter. TD Asset Management Inc boosted its stake in Medpace by 195.2% during the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock valued at $143,162,000 after purchasing an additional 308,816 shares in the last quarter. Wasatch Advisors Inc. increased its position in shares of Medpace by 12.1% during the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company’s stock valued at $446,338,000 after purchasing an additional 294,103 shares during the period. Invesco Ltd. lifted its holdings in shares of Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after buying an additional 246,775 shares during the period. Finally, Millennium Management LLC lifted its holdings in Medpace by 102.3% in the 4th quarter. Millennium Management LLC now owns 450,938 shares of the company’s stock valued at $95,784,000 after acquiring an additional 228,001 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.
Medpace Stock Performance
MEDP opened at $374.32 on Friday. The company has a market cap of $11.60 billion, a PE ratio of 42.15, a price-to-earnings-growth ratio of 2.03 and a beta of 1.38. Medpace has a 1 year low of $185.43 and a 1 year high of $419.42. The firm has a 50 day moving average price of $394.87 and a 200 day moving average price of $319.06.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Monday, February 12th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.24. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company had revenue of $498.40 million during the quarter, compared to analyst estimates of $498.72 million. During the same quarter in the prior year, the business earned $2.12 earnings per share. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. On average, sell-side analysts predict that Medpace will post 10.53 earnings per share for the current year.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
- Five stocks we like better than Medpace
- Using the MarketBeat Stock Split Calculator
- Comprehensive PepsiCo Stock Analysis
- 3 Warren Buffett Stocks to Buy Now
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- CD Calculator: Certificate of Deposit Calculator
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.